Among participants achieving CR, all received combination therapy (mTOR inhibitor with chemotherapy in rhabdomyosarcoma with PI3K or FGFR4 gain-of-function mutations; irinotecan combination therapy in neuroblastoma with an ATRX mutation). Here, FGFR4 is linked to neuroblastoma.